Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Sponsor: CHU de Quebec-Universite Laval
Summary
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2026-01-05
Completion Date
2029-12
Last Updated
2026-01-07
Healthy Volunteers
No
Interventions
Target trough IgG level of 8-10 g/L
Target trough IgG level of 8-10 g/L
Target trough IgG level 4-6 g/L
Target trough IgG level of 4-6 g/L
No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L
If, during follow-up, the patient presents recurrent or severe infections and/or total IgG level less 4 g/L, crossover to group A or B
Locations (1)
Centre Intégré de Cancérologie
Québec, Quebec, Canada